More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints

 
• By Sten Stovall
  
Carcinoma
Roche has 8 Phase III lung cancer studies underway evaluating Tecentriq alone or in combination • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer